Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer

The relative benefit of bevacizumab in ovarian cancer (OC) patients is greater the more the disease becomes platinum-resistant. Among other mechanisms of action, antiangiogenic agents may induce homologous recombination deficiency. Cyclin E1 (CCNE1) overexpression is a proposed marker of platinum re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Adriana Regina Gonçalves, Salvadori, Marcella Marineli, de Brot, Louise, Bovolin, Graziele, Mantoan, Henrique, Ilelis, Felipe, Rezende, Mariana, do Amaral, Nayra Soares, Sanches, Solange Moraes, Maya, Joyce Maria Lisboa, dos Santos, Elizabeth Santana, Pereira, Ronaldo, de Souza Castro, Fabrício, da Nogueira Silveira Lima, João Paulo, Guimarães, Andrea Paiva Gadelha, Baiocchi, Glauco, da Costa, Alexandre André Balieiro Anastácio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426016/
https://www.ncbi.nlm.nih.gov/pubmed/34567247
http://dx.doi.org/10.3332/ecancer.2021.1262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426016/
https://www.ncbi.nlm.nih.gov/pubmed/34567247
http://dx.doi.org/10.3332/ecancer.2021.1262

Ejemplares similares